Previous 10 | Next 10 |
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine PR Newswire LEXINGTON, Mass. , July 11, 2023 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: P...
Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society PR Newswire LEXINGTON, Mass. , June 15, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative i...
Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention PR Newswire Presentation will showcase Company's patented iSPERSE™ technology and positive topline results from Phase 1 study of PUR3100 for acute migraine ...
2023-05-12 11:45:18 ET Pulmatrix press release ( NASDAQ: PULM ): Q1 GAAP EPS of -$1.22. Revenue of $1.5M (+29.3% Y/Y). For further details see: Pulmatrix GAAP EPS of -$1.22, revenue of $1.5M
Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Patient dosing initiated for Phase 2b study of PUR1900 for ABPA Phase 1 study of PUR3100 for migraine achieves positive topline results $30.8 million in c...
Pulmatrix Supports World Asthma Day 2023 PR Newswire LEXINGTON, Mass. , May 2, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central...
2023-03-30 09:58:44 ET Pulmatrix press release ( NASDAQ: PULM ): FY GAAP EPS of -$5.46. Revenue of $6.1M (+17.3% Y/Y). Research and development expense was $18.2 million for the year ended December 31, 2022, as compared to $15.4 million for the year ended December 31, ...
Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update PR Newswire PUR1900 Phase 2b study dosed first patients in Q1 2023 PUR3100 Phase 1 study achieves positive topline results as announced in Q1 2023 $35.6 million in ...
Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma PR Newswire LEXINGTON, Mass. , Feb. 6, 2023 /PRNewswire/ -- Pulmatrix, Inc. ( NASDAQ : PULM ...
Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment" PR Newswire LEXINGTON, Mass. , Jan. 25, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutica...
News, Short Squeeze, Breakout and More Instantly...
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation PR Newswire Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket ® inhalation device. Pulmatrix transferring leased building,...
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) PR Newswire Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) a...